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BACKGROUND: Oesophageal cancer incidence is increasing and survival rates remain extremely poor. Natural agents with potential for
chemoprevention include the phytochemical curcumin (diferuloylmethane). We have examined the effects of curcumin on a panel of
oesophageal cancer cell lines.
METHODS: MTT (3-(4,5-dimethyldiazol-2-yl)-2,5 diphenyl tetrazolium bromide) assays and propidium iodide staining were used to
assess viability and DNA content, respectively. Mitotic catastrophe (MC), apoptosis and autophagy were defined by both
morphological criteria and markers such as MPM-2, caspase 3 cleavage and monodansylcadaverine (MDC) staining. Cyclin B and
poly-ubiquitinated proteins were assessed by western blotting.
RESULTS: Curcumin treatment reduces viability of all cell lines within 24h of treatment in a 5–50mM range. Cytotoxicity is associated
with accumulation in G2/M cell-cycle phases and distinct chromatin morphology, consistent with MC. Caspase-3 activation was
detected in two out of four cell lines, but was a minor event. The addition of a caspase inhibitor zVAD had a marginal or no effect on
cell viability, indicating predominance of a non-apoptotic form of cell death. In two cell lines, features of both MC and autophagy were
apparent. Curcumin-responsive cells were found to accumulate poly-ubiquitinated proteins and cyclin B, consistent with a disturbance
of the ubiquitin–proteasome system. This effect on a key cell-cycle checkpoint regulator may be responsible for the mitotic
disturbances and consequent cytotoxicity of this drug.
CONCLUSION: Curcumin can induce cell death by a mechanism that is not reliant on apoptosis induction, and thus represents a
promising anticancer agent for prevention and treatment of oesophageal cancer.
British Journal of Cancer (2009) 101, 1585–1595. doi:10.1038/sj.bjc.6605308 www.bjcancer.com
Published online 6 October 2009
& 2009 Cancer Research UK
Keywords: curcumin; apoptosis; mitotic catastrophe; autophagy; oesophageal cancer
                                                       
Oesophageal cancer is the eighth most common cancer and the
sixth most common cause of death from cancer (Parkin et al,
2005). Despite advances in surgery and neoadjuvant therapy, 5-
year survival rates for oesophageal cancer are between 10 and 15%
for the United States and 10% for Europe (Sant et al, 2003). The
pathogenesis of this cancer still remains unclear, making the
prediction of sensitivity to current chemotherapeutic regimes very
difficult. The development of new agents for treatment of this
cancer is imperative, requiring a more novel and integrated
approach to prevention, diagnosis and treatment.
Tumour cell resistance to apoptosis is an inherent part of the
carcinogenic process and is also implicated in resistance to
chemotherapeutic drugs (Johnstone et al, 2002). Therefore, new
approaches are required to target resistant cells and improve
efficacy without toxicity. Recent attention has focused on
phytochemicals as anticancer agents. Curcumin is a yellow
pigment found in the rhizome of turmeric (Curcuma longa), and
has been attributed to various properties including, antioxidant,
anti-inflammatory, anti-angiogenic, anti-proliferative and wound
healing (Sharma et al, 2005), without cytotoxic effects on healthy
cells (Syng-Ai et al, 2004). It has also shown significant
chemopreventive efficacy against various malignancies (Surh,
2003). Several studies have suggested that curcumin induces
apoptotic cell death in malignant cells (Karunagaran et al, 2005)
and to be both p53-dependent and p53-independent (Salvioli et al,
2007). The exact mechanisms of curcumin-induced cell death still
remain ill-defined, with controversial roles for the Bcl-2 family and
reactive oxygen species (Salvioli et al, 2007).
There is also growing evidence that curcumin can induce death
in cells that are resistant to apoptosis (Holy, 2002; Wolanin et al,
2006). Several studies have found that curcumin induces arrest
within the G2/M phases of the cell cycle, together with mitotic
spindle disruption, defects in cytokinesis and micronucleation,
consistent with a type of cell death referred to as mitotic
catastrophe (MC) (Magalska et al, 2006; Wolanin et al, 2006).
More recently, treatment with curcumin has been reported to
induce autophagic cell death in malignant cells (Aoki et al, 2007).
This type of cell death occurs without chromatin fragmentation,
and is characterised by the formation of autophagic vacuoles
(Degterev and Yuan, 2008).
In accordance with the multiple properties and clinical effects
ascribed to curcumin, many cellular targets have also been
proposed. Curcumin has been reported to inhibit diverse targets
such as NF-kB, COX-2 and kinases associated with survival
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ssignalling (IKK, NIK and AKT), cell proliferation (ERK) and cell-
cycle regulation (Aggarwal et al, 2003; Castedo et al, 2004; Duvoix
et al, 2005). More recently, downregulation of the survivin protein
has been implicated in curcumin-induced MC (Magalska et al,
2006; Wolanin et al, 2006).
The ability of curcumin to show a broad range of activity has
been attributed to its ability to affect multiple targets. However,
how curcumin actually achieves this broad-spectrum activity is
unknown. In this study, we have investigated whether curcumin
could have cytotoxic activity against oesophageal cancer cells. It
is likely that this is one of the most suitable cancers for oral
administration of curcumin, because of low bioavailability for
other non-gastrointestinal cancers, and the increasing diagnosis
worldwide of pre-malignant conditions such as Barrett’s
oesophagus.
As oesophageal cancers are often resistant to cell death
induction with chemotherapeutic drugs, we have specifically
examined how curcumin induces cell death, and looked for
molecular features that are associated with susceptibility to this
agent. We have shown that curcumin primarily induces MC in
susceptible cells. In addition, apoptosis or autophagy can
accompany MC – and this is probably dependent on the active
death signalling pathway in a given cell line. We have also
examined additional molecular effects of curcumin that could
potentially account for both its pleiotropic actions and the mitotic
death mechanism. Cytotoxicity correlated with the ability of
curcumin to elevate the levels of poly-ubiquitinated proteins and
to accumulate the mitotic regulator cyclin B1. This is consistent
with evidence that curcumin can influence multiple targets because
of its inhibitory effects on the ubiquitin–proteasome system (UPS)
(Jana et al, 2004; Si et al, 2007).
MATERIALS AND METHODS
Cell lines and culture conditions
Human oesophageal squamous and adenocarcinoma cell lines
OE19, OE21 and OE33 (Rockett et al, 1997) were purchased from
the European Collection of Cell Cultures (ECACC). KYSE450 were
purchased from Die Deutsche Managementsystem Zertifizierungs-
gesellschaft mbH (DSMZ, Braunschweig, Germany). The cells were
maintained in RPMI 1640, 1% penicillin/streptomycin, 10% (v/v)
fetal calf serum (FCS, all from Gibco, Paisley, UK) at 371C in 95%
air and 5% CO2.
Cell treatment
Curcumin (Cayman Chemical Co., Ann Arbor, MI, USA) was
dissolved in dimethyl sulphoxide (DMSO) (Sigma, Dublin,
Ireland). Final curcumin concentrations of 5–50mM were obtained
by dilution in culture media such that the final concentration of
DMSO was not 40.07%. Controls containing 0.07% DMSO were
included in all experiments. For inhibition of caspase activity, cells
were treated with Z-Val-DL-Asp-fluoromethylketone (zVAD-fmk)
(Bachem AG, Bubendorf, Switzerland) at a concentration of 25 or
50mM for 1h before curcumin treatment. Cells were treated with
200nM of nocodazole for 18h before MPM-2 expression assay.
Proliferation and viability assays
Cell viability was measured by MTT ((3-(4,5-dimethyldiazol-2-yl)-
2,5 diphenyl tetrazolium bromide); Sigma). After 24h treatment,
MTT (5mgml
 1 in phosphate buffered saline (PBS)) was added to
each well and incubated for 1h at 371C in 95% air and 5% CO2.
Reduced MTT was dissolved in DMSO and measured
spectrophotometrically in a dual-beam microtiter plate reader
(SpectraMax, Molecular Devices, Sunnyvale, CA, USA) at 562 with
a 620-nm reference using SoftMax Pro 4.7.1 software (Molecular
Devices). Experiments were carried out in quadruplicate wells,
repeated at least three times. Values are presented as the mean
absorbance±s.e.m.
Cell cycle analysis
After 24h of treatment with curcumin (5–50mM), cells were
harvested and fixed in 70% ethanol overnight at 41C. Cells
were washed twice in PBS, and resuspended in 500ml of PBS with
20mgml
 1 propidium iodide (PI) (Sigma, Dublin, Ireland) for
30min in the dark. Cell cycle was analysed by flow cytometry
using CellQuest software Becton Dickinson, Oxford, UK on a
FACScan Flow Cytometer (Becton Dickinson, Oxford, UK).
Cell morphology
Cell suspensions (100ml) were cytospun in a Shandon Cytospin 4
Cytocentrifuge (Thermo Scientific, Cheshire, UK) at 400r.p.m. for
2min, air-dried and stained using RapiDiff (Bios Europe,
Lancashire, UK). Slides were mounted with DPX (BDH Labora-
tories, Poole, UK) and visualised using Olympus BX51 system
DP70 camera with Olympus DP3.2 software (Essex, UK).
Mitotic index analysis
The mitotic index was assessed by MPM-2 (anti-phospho-Ser/
Thr-Pro) expression. After 24h of treatment (15–25mM curcumin),
cells were harvested and fixed in 70% ethanol overnight. Cells were
then washed and suspended in 100ml of IFA-Tx buffer (4% FCS,
150nM NaCl, 10nM HEPES, 0.1% sodium azide, 0.1% Triton X-100)
with a primary MPM-2 antibody (1mgml
 1; Upstate Cell Signaling
Solutions, Millipore, Watford, UK) at room temperature for 1h.
Cells were washed and resuspended in IFA-Tx buffer with a rabbit
anti-mouse FITC-conjugated secondary antibody (1:50; Serotec,
Oxford, UK) for 1h at room temperature in darkness. Finally, cells
were washed and resuspended in 500ml of PBS with 20mgml
 1 of
PI (Sigma) for 30min in the dark. MPM-2 expression was analysed
using CellQuest software on a FACScan flow cytometer (Becton
Dickinson).
Western blot analysis
Cells were washed in ice-cold PBS (Gibco) and lysed in ice-cold
RIPA buffer (50mM Tris-HCl (pH 7.4), 1% Igepal, 0.25% sodium
deoxycholate, 150mM NaCl, 1mM EGTA, 1mM Na3VO4,1m M NaF)
with the addition of 1  protease inhibitor cocktail (Sigma) and
1  Pefabloc SC (Fluka, Buchs SG, Switzerland) before use. Protein
estimation of supernatants was carried out using the Bradford
assay. Equal concentrations (50mg) of protein were separated by
SDS–PAGE, transferred to Protran nitrocellulose membrane
(Perkin-Elmer, Boston, MA, USA) and blocked in 5% non-fat
milk in PBS. Membranes were probed with polyclonal anti-
caspase3 antibody at 1:1000 (Cell Signaling Technology Inc.,
Danvers, MA, USA). For the detection of phospho-p44/42 MAP
kinase, membranes were probed with ERK and P-ERK polyclonal
rabbit antibodies (1:1000; Cell Signaling Technology Inc.). Other
antibodies were mouse monoclonal anti-survivin antibody (dilu-
tion at 1:100; Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), rabbit polyclonal anti-ubiquitin antibody (1:1000; Cell
Signaling Technology Inc.) and rabbit polyclonal anti-cyclin B1
(1:500; Santa Cruz Biotechnology Inc). All secondary antibodies
were horseradish peroxidase-conjugated and used at 1:1000
(DakoCytomation, Cambridgeshire, UK). Peroxidase activity was
detected using an enhanced chemiluminescence detection kit
(Amersham Biosciences, Buckinghamshire, UK) and developed on
Kodak film (Sigma). Membranes were re-probed with anti-b-actin
antibody 1:5000 (Sigma).
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sDetection of acidic autophagic vacuoles
Cells were seeded on sterile coverslips in tissue culture
plates (Cover Glasses, Menzel-Glaser, Germany). After curcumin
treatment, cells were incubated with 0.1mM monodansylcadaverine
(MDC) in PBS at 371C for 10min, washed thrice with PBS and
immediately visualised by fluorescent microscopy using an
inverted microscope and an Olympus BX51 system DP70 camera.
Excitation wavelengths were 360–380nm. For analysis and
photography, Olympus DP version 3.2 software were used.
Statistical analysis
Comparison between groups was carried out with paired Student’s
t-test. Values of Po0.05 were considered statistically significant.
Asterisks indicate the level of significance.
RESULTS
Effects of curcumin on cell viability and clonogenicity in
oesophageal cancer cells
We assessed the sensitivity of a panel of oesophageal cancer cell
lines to curcumin. This includes two squamous cell carcinoma
(SCC) cell lines (OE21 and KYSE450) and two adenocarcinoma cell
lines (AC) (OE33 and OE19). All cell lines were treated with 5, 15,
25 and 50mM of curcumin for 24h. Curcumin induced a dose-
dependent reduction in viability in all cell lines, as measured by
the MTT assay (Figure 1A). However, the OE19 cell line was less
affected at lower concentrations.
As the MTT assay evaluates a metabolic activity, we further
assessed whether viability was indeed lost by assessing the capacity
of the cultures to recover from treatment after removal of
curcumin. Cells were incubated with curcumin for 24h and then
allowed to recover without drug for a further 48h. Concentrations
in excess of 5mM markedly reduced the recovery of all cell lines,
indicating substantial loss of viability. The OE19 cells showed
greater resistance and were better able to recover at 15 and 25mM
concentrations (Figure 1B). According to the MTT assay, the
cell lines can be ranked in the following order regarding
their ability to recover after curcumin treatment: KYSE4504
OE214OE334OE19. The KYSE450 and OE21 cell lines
cannot recover from curcumin treatment at concentrations higher
than 15mM.
Effect of curcumin on the cell cycle and mitotic index
We then examined cell-cycle distribution for each of the cell
lines after treatment with a range of curcumin concentrations
(Figure 2Ai). These data show G2/M accumulation with increasing
concentrations of curcumin in three out of four cell lines. The
more resistant OE19 cell line failed to show G2/M accumulation at
the concentrations shown. Interestingly, the most sensitive cell
lines (KYSE450 and OE21), which have undergone significant cell
death in the 15–50mM range, do not show significant sub-G1 DNA
content, which would be typical if apoptosis was induced. The
percentage of cells in G2/M phases of the cell cycle increased with
higher concentrations of curcumin (Figure 2Aii) in all three
sensitive cell lines.
In order to distinguish G2 arrest from mitotic arrest, we also
examined an additional marker. MPM-2 is an antibody that
recognises a group of proteins whose epitopes are exclusively
phosphorylated during mitosis – particularly early prophase to
metaphase (Davis et al, 1983) and it is commonly used as an
indicator of mitotic disturbance. As a positive control, cells were
treated with nocodazole, a known inducer of metaphase arrest
(Vassilev et al, 2006). Treatment of KYSE450 cells with nocodazole
for 18h resulted in a synchronisation of the entire cell population
in the G2/M phase and an increase in MPM-2 labelling from 0.15 to
23.5% (Figure 2B). In all cells treated with 25mM of curcumin,
MPM-2 staining was elevated above control levels (21.61, 9.43, 6
and 3.86% for KYSE450, OE21, OE33 and OE19, respectively)
(Figure 2B). Staining was not as strong as that achieved with
nocodazole, possibly because the G2M accumulation was not as
marked (except in KYSE450 cells). It is also likely that the cells are
in various stages of mitosis, which are not all identified with this
early prophase marker. Therefore, the elevated staining of MPM-2
suggests mitotic disturbance – but may also underestimate it.
Morphological analysis of oesophageal cancer cells after
24h of curcumin treatment
Curcumin susceptibility in these oesophageal cells is associated
with induction of a cell-cycle arrest within the G2/M stages and
mitotic disturbance. Other studies have reported that curcumin
can induce MC, which is currently defined primarily by
morphology (Kroemer et al, 2009). We therefore examined the
morphology of curcumin-treated cells. Figure 3A shows represen-
tative examples of both treated and untreated cell lines. After 24h
treatment with concentrations as low as 15mM, a marked elevation
in the number of cells with visibly distinct chromosomes was
observed. Many showed a distinct chromatin image suggestive of a
monopolar spindle and duplicated but unseparated chromosomes,
which are centrally located in the cells (Figure 3A–M). In most
cells, the nuclear membrane is absent and cells appear unable to
progress beyond metaphase. In addition, some large cells with an
extra nuclei were observed. These distinct morphologies were
present and predominant in the three sensitive cell lines.
In addition to features of MC, the curcumin-treated OE21 and
OE33 cell lines also show a subpopulation of cells with clear
classical apoptosis morphology: chromatin condensation,
cytoplasm shrinkage, and the formation of apoptotic bodies
(Figure 3A (A)). Untreated control OE21 and OE33 cell lines also
have a minor background of apoptotic cells. Apoptotic cells were
very rarely found in the KYSE450 or OE19 population. After
treatment with 15mM of curcumin, KYSE450 cells predominantly
show MC, but other morphological features also coexist in the cell
population. These include nuclear pyknosis and vacuolisation of
the cytoplasm. OE19 cells treated with the same concentration of
curcumin preserve their overall structural features similar to
untreated cells. Much higher concentrations (X50mM) show
similar morphology to KYSE450 cells.
Cells treated with 15mM of curcumin were counted (Figure 3Bii)
according to morphology (apoptotic, non-apoptotic/MC-like and
autophagy-like) and expressed as the percentage of the total cell
population. All three morphologies were visible in KYSE450-
treated cells, but MC was the predominant morphology (25.4%).
KYSE450 cells expressed the highest levels of autophagy-like
morphology (22.3%), and the lowest level of apoptosis of all three
sensitive cell lines (5.0%). OE21 and OE33 cells show a higher
percentage of apoptotic morphology (15.1 and 13.4%,
respectively), but MC is more prevalent (25.2 and 22.2%,
respectively). OE19 cells show low levels of aberrant morphology.
Overall, aberrant morphology counted for B50% of the total cell
population in sensitive cell lines, which correlates with our initial
cell survival data (Figure 1A).
KYSE450 is the most sensitive cell line as evaluated by MTT
assay and showed marked cell-cycle arrest in G2/M phase. It is also
a cell line where apoptosis appears to be rare after treatment. The
dramatic vacuolisation of the cytoplasm without apparent loss of
nuclear material is consistent with the described macrostructure
of autophagy (F) (Figure 3A) (Kroemer et al, 2009). This type of
autophagic morphology in the KYSE450 cell line has also been
observed by our group in response to treatment with cytotoxic
drugs such as 5-fluorouracil and cisplatin (unpublished data).
Interestingly, the features of MC and those of autophagy were not
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possible that the vesicles are just smaller in a cell exhibiting MC, or
obscured by the dramatic chromatin morphology.
Therefore, this analysis indicates that the primary morphology
in susceptible cells resembles that described for MC. The two most
susceptible cells lines also show different additional subpopula-
tions. OE21 cells show a minor population with apoptotic
morphology and the KYSE450 cells show an additional population
with features of autophagy. OE33 and OE19 also show minor
populations of apoptosis and autophagy, respectively.
Examination of caspase-3 activity
Various papers have suggested that MC is an independent death
process, whereas others have proposed that MC is just
a consequence of mitotic failure that leads to apoptosis
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Figure 1 Assessment of sensitivity and clonogenicity of squamous cell carcinoma and adenocarcinoma oesophageal cell lines to curcumin. (A) Effects of
curcumin on cell viability. After treatment with 5, 15, 25 and 50mM of curcumin for 24h, cell viability was determined by MTT assay, with values presented as
mean absorbance. *Po0.05, **Po0.005 and ***Po0.0005 compared with untreated cells (paired Student’s t-test). Bars¼s.e.m. (B) To determine
whether or not the cells could overcome the effects of the drug and recover, the curcumin was removed after 24h of treatment. Cells were allowed to
recover for a further 48h and the MTT assay was repeated. Cell clonogenicity was calculated as the percentage of the control. *Po0.05, **Po0.005 and
***Po0.0005 compared with untreated cells (paired Student’s t-test). Bars¼s.e.m.
Curcumin induced cell death in oesophageal cancer cells
G O’Sullivan-Coyne et al
1588
British Journal of Cancer (2009) 101(9), 1585–1595 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(Castedo et al, 2004; Vakifahmetoglu et al, 2008). We therefore
looked for the presence of active caspase-3, which is an indicator
of classical apoptosis. Western blot analysis was used to assess the
levels of cleavage of pro-caspase 3 (35kDa) to active caspase-3
(17kDa). OE21 and OE33 cell lines showed active caspase-3 after
curcumin treatment, consistent with their morphological features
(Figure 4A). KYSE450 and OE19 cell lines do not show a significant
increase in active caspase-3 with curcumin treatment, which is also
consistent with rare apoptotic morphology. It is also notable from
the western blot analysis of caspase isoforms that, although active
caspase 3 is detectable in OE21 and OE33 cell lines, the majority of
the total protein is in the uncleaved pro-caspase form and its
contribution to the death process may be relatively minor.
We therefore examined the consequences of caspase inhibition
on cell viability.
Cells were pretreated with the pan-caspase inhibitor zVAD-fmk
and the effect on cell death induced by 25mM of curcumin was
assessed by MTT assay. In OE21 cell lines, the addition of zVAD-
fmk at 25 or 50mM concentration marginally improved only cell
viability (Figure 4B), which is consistent with morphological
evidence of a minor apoptosis population. In all other cells, the
addition of zVAD-fmk does not improve cell viability. These
results suggest that a non-apoptotic form of cell death predomi-
nates in all of the cell lines with curcumin treatment.
Induction of autophagy with curcumin treatment
Our results thus far suggest that sensitivity to curcumin is
consistent with the induction of MC (with a minor induction of
apoptosis in OE21 cells). However, it is clear that another type of
cell death coexists in the KYSE450 cell line and, to a lesser extent,
in the more resistant OE19 cells. These KYSE450 cells show
extensive cytoplasmic vacuolisation, which is consistent with the
morphology described for autophagy. Autophagy is a process that
sequesters cytoplasmic proteins or organelles into a lytic
compartment that facilitates degradation and re-cycling (Xie and
Klionsky, 2007). This can promote cell survival during cell stress;
however, excessive autophagy can also lead to cell death (Degterev
and Yuan, 2008). To investigate whether autophagy coexisted in
the cell lines after curcumin treatment, we used the MDC assay,
which is a selective fluorescent marker of autophagic vesicles
(Biederbick et al, 1995). The dye shows diffuse staining in
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Figure 2 (A) (i) Assessment of DNA content in oesophageal cancer cell lines after 24h of treatment with curcumin. DNA content analysis was carried
out by propidium iodide staining and flow cytometry after 24h of treatment with increasing concentrations of curcumin. A total of 10000 cells were counted
for each cell line and concentration. Images correspond to typical histogram distributions for each cell line at 0, 15, 25mM of curcumin. The percentage of
cells in the G2/M phase of the cell cycle was estimated using CellQuest software. (ii) The percentage of cells arrested in G2/M phase of the cell cycle.
Columns are means of three experiments. Bars¼s.d. (B) MPM-2 (anti-phospho-Ser/Thr-Pro) expression in untreated and treated oesophageal cancer cells.
MPM-2 is an antibody that recognises a group of proteins that are phosphorylated only in mitosis. Cells were dually stained with propidium iodide to analyse
DNA content, and expression was quantified by flow cytometry. As a positive control, KYSE450 cells were treated for 18h with nocodazole, an anti-fungal
agent known to induce metaphase arrest. Cell-cycle analysis and quantification of MPM-2 expression (gated cells) were carried out by flow cytometry after
treatment with 25mM of curcumin for 24h.
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snon-autophagic cells, but is sequestered into punctate vesicular
staining when autophagy is induced. We therefore examined
distribution of the dye in the three curcumin-sensitive cell lines
(OE21, OE33 and KYSE450) after treatment with curcumin.
OE21 and OE33 cells treated with 15mM (and 25mM; data not
shown) curcumin show diffuse and non-vesicular staining of MDC
(Figure 5A). The KYSE450 cell line has weak and diffuse staining of
MDC in untreated cells. However, treated cells show clear
punctate/vesicular staining, which is accentuated at the higher
curcumin concentration. The punctate staining is clearly visible at
the higher magnification of KYSE450 cells (Figure 5B). However, it
should be noted that this staining was not universal, and it may
coexist and be separate from cells showing MC.
Curcumin effects on the UPS and cyclin B1
Our data suggest that susceptibility to curcumin is primarily
associated with the induction of arrest within G2/M phase and MC.
The primary target of curcumin is unknown; however, an
emerging body of evidence suggests that this compound may
achieve its diverse effects through inhibition of the UPS (Henke
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Figure 3 Morphological features of curcumin-induced cell death in oesophageal cancer cell lines. Cell morphology was visualised using RapiDiff staining by
light microscopy after treatment with 15mM of curcumin for 24h. (A) Typical cytospin images for untreated and curcumin-treated oesophageal cancer cell
lines. Curcumin treatment (15mM) produced a distinct morphology suggestive of a monopolar spindle and duplicated but unseparated chromosomes
centrally located in the cell (M); features are consistent with chromatin images described for mitotic catastrophe (MC). In addition to MC, OE21 and OE33
cell lines show a minor population of cells with clear apoptotic morphology (A). Both of these cell lines also have a background of apoptotic cells visible in
their untreated cytospins. By contrast, KYSE450 and OE19 cell lines rarely show apoptotic cells. KYSE450-treated cells predominantly show the typical
nuclear morphological features of MC after curcumin treatment. Other features coexist at a background level, including nuclear pyknosis, vacuolisation of the
cytoplasm or complete loss of the cytoplasmic membrane while the nuclear membrane remains intact; elements consistent morphologically with autophagic
cell death (F). OE19-treated cells preserve their overall structural features at this concentration. (B) (i) Typical chromatin organisations in untreated and
treated cells. (1) Normal mitosis metaphase image with chromosomes along the equatorial plane of the cell. (2) Nuclear features of cells treated with 18h of
nocodazole, with typical micronucleation. (3) Chromatin alignment in cells treated with curcumin for 24h. (ii) Distribution of abnormal morphological
features in RapiDiff-stained slides in all four oesophageal cancer cell lines after treatment with 15mM of curcumin over 24h. Cells were counted on the basis
of their morphology (apoptotic, non-apoptotic/MC and autophagy-like) and expressed as the percentage of the total cell population.
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set al, 1999; Uhle et al, 2003; Jana et al, 2004; Si et al, 2007). We
therefore looked for evidence of the accumulation of poly-
ubiquitinated proteins after treatment. Cells were treated with 15
and 25mM of curcumin for 24h and analysed for the presence of
poly-ubiquitinated proteins by western blotting. High-molecular-
weight staining increased in a dose-dependent manner – with
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shighest staining evident in the most sensitive cells lines
(Figure 6A). Although we currently cannot distinguish this as a
mechanism or a consequence of MC, our data are clearly
supportive of the UPS contributing a role in the action of this
compound.
The UPS is known to have a major role in cell-cycle regulation –
particularly at the mitotic checkpoint. CDK1/cyclin B1 accumu-
lates in the G2 phase, at the G2/M border. UPS-mediated
degradation of cyclin B1 is then required for cell-cycle progression
through mitosis (Kops et al, 2005; Vassilev et al, 2006). If the UPS
system is inhibited in these cell lines, then cyclin B1 is likely to
accumulate and may contribute to the major disturbances in
mitotic checkpoints. We therefore examined expression after
treatment with 15 and 25mM of curcumin. Cyclin B1 expression
increased in a dose-dependent manner after curcumin treatment of
KYSE450, OE21 and OE33 cell lines (Figure 6B). The OE19 cell line
has low baseline expression of cyclin B1 and does not undergo
detectable changes in expression. The elevation in cyclin B1 levels
in sensitive cells corresponds with increased levels of protein
ubiquitination and induction of arrest within the G2/M phase. It is
therefore possible that cyclin B1 elevation contributes to the cell-
cycle disturbance that is evident in these cells, but many other
proteins are likely to be upregulated as a consequence of
disturbances of the UPS and could contribute to the cytotoxicity
that follows in the form of MC, apoptosis or autophagy.
DISCUSSION
Curcumin has shown potential as both a chemopreventive agent
and a chemotherapeutic agent in various gastrointestinal cancers,
and initial studies in oesophageal cancer have been encouraging
(Ushida et al, 2000). In this study, we have investigated the effects
of curcumin on panel of genetically and phenotypically hetero-
geneous oesophageal cancer cell lines. We have investigated the
cell death mechanisms induced, and also examined additional
molecular features associated with cytotoxicity.
Curcumin was shown to inhibit cell proliferation and viability,
but susceptibility varied between cell lines. The most sensitive cell
lines (KYSE450, OE21 and OE33) underwent mitotic arrest with
morphological features of MC (Castedo et al, 2004; Vitale et al,
2005). The published literature is divided as to whether MC is an
event that precedes apoptotic cell death or is a distinct mechanism
of cell death (reviewed in Vakifahmetoglu et al, 2008). Although
morphological analysis did show apoptotic cells in OE21 and
OE33, these are coexistent but not dominant features of curcumin-
treated cell populations. If apoptosis was the only death
mechanism, the low level of apoptosis is not consistent with the
complete inability of OE21 cells to recover after treatment with
15mM of curcumin. The actual death is therefore morphologically
distinct from apoptosis. Other authors have reported biochemical
features of apoptosis in cell populations showing MC morphology
Curcumin (M)
-Actin
Unt 25 Unt 25 Unt 25 Unt 25
OE21 OE33 KYSE450 OE19
OE21 OE33
OE19 KYSE450
Curcumin
Curcumin only
+25 M zVAD
+50 M zVAD
%
 
o
f
 
v
i
a
b
i
l
i
t
y
100
75
50
25
0
%
 
V
i
a
b
i
l
i
t
y
100
75
50
25
0
%
 
V
i
a
b
i
l
i
t
y
100
75
50
25
0
%
 
V
i
a
b
i
l
i
t
y
100
75
50
25
0
%
 
V
i
a
b
i
l
i
t
y
15 M 25 M 15 M 25 M
15 M 25 M 15 M 25 M
** *
Figure 4 Caspase-3 activity and cell viability after treatment with zVAD and curcumin. (A) All four cell lines were treated with 25mM of curcumin for 24h.
Active caspase-3 activity was estimated by western blotting using equal amounts (40mg) of whole-cell lysates. b-Actin was used as a loading control. The
western blot shown is representative of three independent experiments. (B) Cell viability estimated by MTT assay in all four oesophageal cancer cell lines
after treatment with curcumin and pan-caspase inhibitor zVAD-fmk for 24h. Data was expressed as the percentage of the control. *Po0.05 and **Po0.005
compared with untreated cells (paired Student’s t-test). Bars¼s.d.
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s– primarily caspase activation, although indeed with minimal
caspase 3 cleavage (Rashmi et al, 2004, 2005). Another study also
reported that caspase activation was not required for MC and that
activation of caspases varied in different cell lines (Mansilla et al,
2006). Clearly, limited caspase activation in a heterogeneous
population of cells (as in OE21 cells) does not necessarily mean
that the MC cells are activating caspases. We have found minimal
caspase 3 cleavage in two of our four cell lines (OE21/OE33) and
only marginal protective effects of caspase inhibition on viability
in one cell line. These results collectively suggest that caspase-
dependent apoptosis is not of major importance for curcumin-
induced cytotoxicity and that MC may be occurring as an
independent death mechanism or is part of an undefined
mechanism.
The KYSE450 cell line is particularly sensitive to curcumin and
cells show predominantly MC morphology after treatment.
However this coexists with cells that show high levels of
cytoplasmic vacuolisation, retention of the nuclear membrane
and distinct vesicular MDC staining, indicative of autophagy. The
morphology suggests that MC did not occur in the same cells as
those undergoing autophagy-like cell death, but we cannot rule
this out. Other authors have recently reported exclusive autophagic
cell death after curcumin treatment and this was associated with
the activation of ERK signalling (Aoki et al, 2007; Shinojima et al,
2007). However, we found de-phosphorylation of ERK after
curcumin treatment (Supplementary data). It is possible that this
difference is cell-line-related – or dose-related – as our study used
much lower concentrations of drug (Aoki et al 80mM and our study
15/25mM). A number of studies have also linked downregulation of
survivin with MC (Magalska et al, 2006; Wolanin et al, 2006). We
did not see a correlation between low survivin expression
and induction of MC in the oesophageal cancer cells
(Supplementary data).
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Figure 5 Examination of autophagic cell death in OE21, OE33 and KYSE450 cell lines after treatment with increasing concentrations of curcumin for 24h.
Autophagic vacuoles were identified after incubation of the cells with the selective fluorescent probe monodansylcadaverine (MDC) and visualised
immediately by fluorescent microscopy. (A) Fluorescent photographic images of curcumin-sensitive cell lines, OE21, OE33 and KYSE450. Images correspond
to untreated and 15mM of curcumin at 24h after incubation with MDC. Photographs are representative of two different experiments. Original magnification,
 40. (B) Detailed photograph of the distinct punctate staining in KYSE450 cells after treatment with 15mM of curcumin and incubation with MDC. Original
magnification,  100.
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Figure 6 Poly-ubiquitination and cyclin B1 expression in oesophageal
cancer cell lines after treatment with increasing concentrations of curcumin
for 24h. (A) Effects of curcumin treatment on poly-ubiquitination. Equal
amounts (30mg) of whole-cell lysates were separated using SDS–PAGE
and protein poly-ubiquitination assessed by western blotting with an anti-
ubiquitin antibody. Accumulation of high-molecular-weight ubiquitin
complex is evident after curcumin treatment. (B) Cyclin B1 expression in
oesophageal squamous and adenocarcinoma cell lines. Equal amounts
(30mg) of whole-cell lysates were separated using SDS–PAGE and protein
expression assessed by western blotting with an anti-cyclin B1 antibody.
b-Actin was used as a loading control. The western blot shown is
representative of three independent experiments.
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sIn this panel of oesophageal cells, the induction of MC was the
primary determinant of cytotoxicity. As this can be accompanied
by either apoptosis or autophagy – depending on the cell line – the
secondary death mechanism must depend on the genetic
competency of the cell line, and therefore the induction of either
apoptosis or autophagy is not the determinant of sensitivity.
A particularly encouraging aspect to this study is the fact that
the induction of MC appears to be a separate distinct death process
that could potentially eliminate cancer cells when other death
processes fail. The KYSE450 cell line is highly resistant to 5-FU and
cisplatin, fails to induce apoptosis but induces primarily an
autophagic response (unpublished data). Yet, when treated with
curcumin, this cell line is the most sensitive – and death is
primarily associated with MC. The OE19 cell line is also apoptosis-
incompetent in response to cisplatin and 5-FU – and will undergo
MC in response to curcumin – although at much higher
concentrations (data not shown). The clinical implications of
these results are clear: it is possible that one of the factors affecting
poor response to chemotherapy is the presence of ‘apoptosis-
incompetent’ cells. The ability to undergo autophagy may not
necessarily be helpful, as it can contribute to cell survival. The
existence of MC as an alternative cell death pathway may therefore
offer another possibility for treatment. Curcumin or other inducers
of MC may represent important classes of chemotherapeutics for
apoptosis-incompetent cells.
Despite evidence of curcumin’s potential as an anticancer
cytotoxic agent, we still have little understanding of the
mechanism: clearly, there are different effects on different cell
types. Curcumin has the capacity to be biphasic in its effects: it can
be used to promote wound healing, yet be cytotoxic. This would
suggest that either it has multiple targets that are expressed in a
cell-specific manner or a target that affects cell-specific pathways.
We report in this study that curcumin treatment leads to the
accumulation of poly-ubiquitinated proteins. This was consistent
with cyclin B1 upregulation and G2/M arrest. Our data are
therefore supportive of the view that curcumin acts as an inhibitor
of the UPS (Henke et al, 1999; Jana et al, 2004; Si et al, 2007). This
is likely to have marked effects on the cell cycle, but effects may
differ in different cell lines because of differences in their existing
proteome. For example, cells of a similar type that have lost
transcription of tumour suppressors and/or other cell cycle
inhibitors may differ in their response. Another reported activity
of curcumin that may explain its pleiotropic nature is its effects on
histone modification (Liu et al, 2005). We cannot rule this out, and
clearly more mechanistic work needs to be undertaken in this area.
It is also noteworthy that the UPS system can influence chromatin
structure and thus transcription (O’Connell and Harper, 2007).
In current cancer treatment protocols, the ‘cell death compe-
tency’ of tumours is always undetermined and for many
inaccessible cancers this may never change. It is possible that
chemopreventive or chemotherapeutic regimes may be most
effective if they targeted several death pathways in cancer cells.
At least three different Phase I clinical trials have indicated that
curcumin is safe and well tolerated even at doses as high as
12gday
 1 (Cheng et al, 2001). However, despite its well-
documented efficacy and safety in both animals and humans
in vivo and in vitro, its poor bioavailability has been cited as a
major concern and has probably delayed its development as
a therapeutic agent. Serum concentrations of curcumin after oral
administration range from 0.013 to 11.1mM (Anand et al, 2007).
Various studies have shown curcumin has low bioavailability,
limited tissue distribution, short half-life and a rapid metabolism
irrespective of its route of administration (Ravindranath and
Chandrasekhara, 1981; Garcea et al, 2004, 2005; Hoehle et al, 2006;
Anand et al, 2007). The fact that curcumin has poor systemic
bioavailability would suggest that the gastrointestinal tract is the
most promising site for use in prevention or therapy. However,
novel formulations and metabolism inhibitors attempting to
optimise the pharmacological potency of curcumin have gained
attention, such as the use of piperine, nanoparticles, liposomes,
phospholipid complexes and structurally altered derivatives and
analogues that dramatically improve the biological activity of
curcumin (Shoba et al, 1998; Mishra et al, 2005; Liu et al, 2006;
Anand et al, 2007; Li et al, 2007; Mosley et al, 2007). Combination
studies so far in both in vitro and in vivo have highlighted
promising combinations of curcumin with oxaliplatin (Howells
et al, 2007; Li et al, 2007; Patel et al, 2008) and paclitaxel (Aggarwal
et al, 2005), suggesting there is a very definite potential for
curcumin to be used as part of mainstream clinical regimes.
In summary, curcumin shows features of cytotoxicity,
predominantly consistent with the induction of MC in sensitive
cell lines. This can be accompanied by features of apoptosis or
autophagy, depending on the cell line. As this drug clearly has
activity in apoptosis-resistant cells, it is likely that curcumin and
indeed some of its bioavailability-enhanced analogues are realistic
options to be considered in the future for targeted molecular
cancer prevention and treatment.
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